|Enzymes in Drug Discovery Summit|
Protease Inhibitors in Drug Discovery
Ubiquitin Research and Drug Discovery
Protein Kinases in Drug Discovery
We are pleased to announce the 4th Protease Inhibitors in Drug Discovery Conference, to be hosted by GTCbio on February 22-23, 2018 in San Diego, CA. Though protease inhibitors hold great therapeutic promise in areas such as inflammation, cardiovascular diseases, and cancer, researchers in the field are still overcoming the challenge of specificity for drug design.
This meeting will provide a forum for scientists from both industry and academia to share recent advances in protease inhibitor research, from biological functions to translational aspects for drug discovery. Speakers will cover topics such as regulation of proteases by exosites, drug design of protease inhibitors, membrane-associated proteolysis, and many more. In addition to cutting-edge scientific presentations, attendees will be able to form new connections during dedicated networking sessions.
We hope to see you there!
The 2018 Advisory Committee
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
The 2018 sponsorship is currently in process.
Please come back and visit this page for updates.
BELOW ARE THE SPONSORS FROM 2017.
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
Reaction Biology Corp. is a CRO that specializes in epigenetic and kinase HTS and profiling services. RBC’s radioisotope based assays feature the largest collection of kinase & epigenetic targets available to the industry, including more than 559 kinases, 100+ reader domains, >30 methyltransferases, all HDACs and SIRTs, demethylases and more. RBC also produces high quality epigenetic proteins that are available for purchase.
Carna is a leading provider of protein kinases, drug resistant mutants and related kinase inhibitor drug discovery assay services, including cell-based assays. We also offer an industry leading high-throughput pathway mapping service and cell line development services for the study of protein-protein interactions.